New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers

NCT ID NCT07416123

Recruiting now Disease control Sponsor: Genmab Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants receive the active drug, and the trial lasts about 17 months per person.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GEN1106 (a biologic drug given by IV infusion)
What this could lead to: If successful, this could point toward a new treatment option for people with certain advanced solid tumors, including bladder cancer.
What could go wrong: This is a very early phase 1 trial with only 103 participants. The main goal is safety, not effectiveness, and many experimental cancer drugs fail in early testing. Side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm transitional cell carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS UROTHELIAL CARCINOMA

Contacts and locations

Locations

Carolina Urologic Research Center
RECRUITING

Myrtle Beach, South Carolina, 29572, United States
Hospital HM Nou Delfos
RECRUITING

Barcelona, Spain
Hospital Universitario Quironsalud Madrid
RECRUITING

Madrid, 28223, Spain
National Cancer Center Hospital
RECRUITING

Chuo Ku, Tokyo, 104-0045, Japan
START Madrid - Centro Integral Oncologico Clara Campal
RECRUITING

Madrid, 28050, Spain
START Madrid - Hospital Universitario Fundacion Jimenez Diaz
RECRUITING

Madrid, 28040, Spain
START New York Long Island LLC
RECRUITING

Lake Success, New York, 11042, United States
South Texas Accelerated Research Therapeutics
RECRUITING

San Antonio, Texas, 78229, United States
West Cancer Center and Research Institute
NOT_YET_RECRUITING

Germantown, Tennessee, 38138, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.